Analyst Price Targets — IMMX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 22, 2026 2:38 pm | Robert Burns | H.C. Wainwright | $20.00 | $8.92 | TheFly | Immix Biopharma price target raised to $20 from $15 at H.C. Wainwright |
| March 27, 2026 10:12 am | — | H.C. Wainwright | $15.00 | $8.15 | TheFly | Immix Biopharma price target raised to $15 from $12 at H.C. Wainwright |
| February 9, 2026 10:35 am | Graig Suvannavejh | Mizuho Securities | $14.00 | $6.74 | TheFly | Immix Biopharma initiated with an Outperform at Mizuho |
| December 9, 2025 1:26 pm | — | H.C. Wainwright | $12.00 | $6.38 | TheFly | Immix Biopharma price target raised to $12 from $8 at H.C. Wainwright |
| July 1, 2024 6:08 am | Robert Burns | H.C. Wainwright | $7.00 | $1.98 | TheFly | Immix Biopharma initiated with a Buy at H.C. Wainwright |
Latest News for IMMX
Immix Biopharma (IMMX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
BofA Securities initiates Immix Biopharma with Buy rating, citing NXC-201's potential in AL amyloidosis and peak sales near $963 million.
The consensus price target hints at an 113.6% upside potential for Immix Biopharma (IMMX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
The consensus price target hints at a 120.6% upside potential for Immix Biopharma (IMMX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
- Financing includes leading U. S. biotechnology institutional investors and mutual funds - LOS ANGELES, CA, May 22, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. ("ImmixBio", "Company", "We" or "Us" or "IMMX"), a global leader in AL Amyloidosis, today announced the closing of its previously announced underwritten registered offering of 16,778,524 shares of its common stock at a price to the public of $8.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for IMMX.
U.S. House Trading
No House trades found for IMMX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.